Effects of Systemically Administered Hydrocortisone on the Immune System in Healthy Volunteers
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Background:
- Corticosteroids have been used to treat inflammation and immune system diseases for decades. However, despite their widespread use, there is little information on the specifics of how corticosteroids affect the immune system in humans. The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases is interested in studying how the steroid hormone hydrocortisone affects the immune system in healthy volunteers, and in doing so to understand how hydrocortisone given at different doses works in treating many immune and inflammatory conditions.
Objectives:
- To evaluate the effects of hydrocortisone on the immune and inflammatory responses of healthy volunteers over the short and intermediate term (up to 28 days after administration).
Eligibility:
- Healthy volunteers at least 18 years of age.
Design:
- Participants will be screened with a full medical history and physical examination, and blood and urine tests. At this visit, participants will be separated into two groups, with each group scheduled to receive a different amount of hydrocortisone during the study visit.
- One week before the study visit, participants will provide a blood sample for baseline testing.
- Participants will be admitted for a 24-hour inpatient stay that will involve frequent blood draws. Between blood draws, participants will be able to work, watch TV, walk around, and so on, and will be provided with regular meals.
- Blood will be drawn 1 hour before the infusion of hydrocortisone. Participants will be divided into two further sets of groups with different blood draw schedules:
- Groups 1 (lower dose) and 2 (higher dose) will have blood draws 1, 4, 8, 12, and 24 hours after the hydrocortisone infusion.
- Groups 3 (lower dose) and 4 (higher dose) will have multiple blood draws over 24 hours, with timing based on data from the previous groups' blood test results.
- Participants will provide additional blood samples 7 and 28 days after the in-patient visit.
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Effects of Systemically Administered Hydrocortisone on the Human Immunome in Healthy Volunteers |
- Effects of hydrocortisone on the human immune
| Estimated Enrollment: | 50 |
| Study Start Date: | January 2011 |
Corticosteroids have been in widespread therapeutic use as anti-inflammatory and immunomodulatory agents for decades, and there is a wealth of information on their immunosuppressive effects in animals and in human cells cultured in vitro. However, despite their ubiquitous clinical use, there is a paucity of information on the effects of corticosteroids administered to humans systemically, and no previous study has examined their effects on the human immunome.
Therefore the Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects at baseline, and then at various time points after administration of 250 mg and 50 mg of intravenous hydrocortisone. These samples will be used to perform a comprehensive and detailed analysis of the immune system in response to corticosteroid administration. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in healthy adult subjects after administration of corticosteroids. This information may be useful in understanding the mechanistic effects of this commonly prescribed class of medications in humans.
The primary objective is to perform laboratory studies to characterize the immune response in healthy adult volunteers after administration of moderate (250 mg) and low (50 mg) doses of the glucocorticoid hydrocortisone. Primary endpoint is the results of the research laboratory assessments. As samples will be stored indefinitely, the time frame for primary endpoint is indefinite.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
- INCLUSION CRITERIA:
Healthy volunteer (health status confirmed by History and Physical Exam and blood work)
Ages 18 years or older (no upper limit)
Must be willing to allow samples to undergo genetic studies
EXCLUSION CRITERIA:
Patients with diseases with an inflammatory or immune component
Patients who have irregular circadian rhythms, i.e. those who are blind or work night shifts
Patients with active infections requiring systemic antibiotic therapy
Use of immune modifying medications, i.e. NSAIDs (such as aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve), celecoxib (Celebrex), ketorolac (Toradol) within the past month
Systemic fungal, viral, or mycobacterial infections
Persons who are alcoholic or abusers of illicit substances
Abnormal fasting glucose > 100mg/dL
Female subjects may not be pregnant or lactating due to possible side effects of use of hydrocortisone in a non-benefit study
Liver function tests (AST, ALT, total bilirubin, alkaline phosphatase) above the normal laboratory reference range
Other contraindications to corticosteroids (i.e. gastrointestinal ulceration, Cushing's syndrome, congestive heart failure, uncontrolled hypertension, glaucoma, osteoporosis, or known hypersensitivity to corticosteroids)
Corticosteroid use within the last six months prior to enrollment, including topical, intra-articular or intramuscular injections, or inhaled administration
Prior use of systemically administered corticosteroids for > 6 months duration
Use of azole medications or chronic opiates
Patients with psychiatric diagnoses or symptoms, to include hypomania, bipolar disorder, major depression, or dysthymia
Patients with a body mass index greater than 30
Subjects unable to comprehend the investigational nature of the study or those who are unable or unwilling to sign the consent
Contacts and Locations| Contact: Paula Schum, R.N. | (301) 402-3796 | schump@mail.nih.gov |
| Contact: Shira Y Perl, M.D. | (301) 594-0512 | perls@mail.nih.gov |
| United States, Maryland | |
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
| Bethesda, Maryland, United States, 20892 | |
| Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL) 800-411-1222 ext TTY8664111010 prpl@mail.cc.nih.gov | |
| Principal Investigator: | Shira Y Perl, M.D. | National Heart, Lung, and Blood Institute (NHLBI) |
More Information
Additional Information:
Publications:
| ClinicalTrials.gov Identifier: | NCT01281995 History of Changes |
| Other Study ID Numbers: | 110092, 11-H-0092 |
| Study First Received: | January 21, 2011 |
| Last Updated: | May 23, 2013 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Institutes of Health Clinical Center (CC):
|
Biologic Samples Hydrocortisone Laboratory Research Specimens Glucocorticoids |
Immune Modulation Healthy Volunteer HV |
Additional relevant MeSH terms:
|
Cortisol succinate Hydrocortisone acetate Hydrocortisone 17-butyrate 21-propionate Hydrocortisone Hydrocortisone-17-butyrate |
Anti-Inflammatory Agents Therapeutic Uses Pharmacologic Actions Dermatologic Agents |
ClinicalTrials.gov processed this record on May 23, 2013